Emergent BioSolutions Inc.
For the period ended Dec 31, 2025. Filed Feb 27, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 27, 2026
EBS$6.05-0.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Financial Statements and Supplementary Data
| Index to Consolidated Financial Statements | Page |
|---|---|
| Report of Independent Registered Public Accounting Firm | 82 |
| Consolidated Balance Sheets for the years ended December 31, 2025 and December 31, 2024 | 84 |
| Consolidated Statements of Operations for the years ended December 31, 2025, December 31, 2024 and December 31, 2023 | 85 |
| Consolidated Statements of Comprehensive Income (Loss) for the years ended December 31, 2025, December 31, 2024 and December 31, 2023 | 86 |
| Consolidated Statements of Cash Flows for the years ended December 31, 2025, December 31, 2024 and December 31, 2023 | 87 |
| Consolidated Statements of Changes in Stockholders’ Equity for the years ended December 31, 2025, December 31, 2024 and December 31, 2023 | 88 |
| Notes to Consolidated Financial Statements | 89 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.